Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PIK3CB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PIK3CB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PIK3CB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PIK3CA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PIK3CA Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PIK3CA sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PHKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PHKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PHKB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PI4K2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PI4K2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PI4K2B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PI4K2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PI4K2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PI4K2A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PI4KB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PI4KB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PI4KB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PHKG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PHKG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PHKG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PEPD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PEPD Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PEPD sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PGPEP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PGPEP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PGPEP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PHEX Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PHEX Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PHEX sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PGK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PGK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PGK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PDXK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PDXK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PDXK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →